Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs [7]

Journal of Clinical Oncology

Volumn 25, Issue 11, 2007, Pages 1449-1450

  Lejeune, Ferdy J ^a   Eggermont, Alexander M M ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MELPHALAN; TUMOR NECROSIS FACTOR;

ADVANCED CANCER; ANGIOGENESIS; APOPTOSIS; CANCER STAGING; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HYPERTHERMIA; LETTER; LIMB PERFUSION; LIVER TOXICITY; MELANOMA; METASTASIS; NEPHROTOXICITY; OSTEOSARCOMA; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; MULTICENTER STUDIES; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 34248136365     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.8459     Document Type: Letter

References (11)

1. Cornett WR, McCall LM, Petersen RP, et al: Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 24:4196-1201, 2006
2. Fraker DL, Alexander H, Ross MI, et al: A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNFa) plus interferon-gamma(IFN). Ann Surg Oncol 9:S8, 2002 (abstr 1)
3. Lienard D, Eggermont AM, Koops HS, et al: Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: A multicentre randomized phase II study. Melanoma Res 9:491-502, 1999
4. Lejeune FJ, Kroon BB, Di Filippo F, et al: Isolated limb perfusion: The European experience. Surg Oncol Clin N Am 10:821-832, 2001
5. Grünhagen DJ, Brunstein F, Graveland WJ, et al: One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 240:939-947, 2004 See "Note" following "References."; discussion 240:947-948, 2004
6. Rossi CR, Foletto M, Mocellin S, et al: Hyperthermic isolated limb perfusion with low dose tumor necrosis factor-alpha and melphalan for bulky in transit melanoma metastases. Ann Surg Oncol 11:173-177, 2004
7. de Wilt JH, ten Hagen TL, de Boeck G, et al: Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 82:1000-1003, 2000
8. Grünhagen DJ, de Wilt JHW, ten Hagen TLM, et al: Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nature Clin Pract Oncol 3:94-103, 2006
9. Eggermont AMM, Schrafford Koops H, Klausner JM, et al: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: The cumulative multicenter European experience. Ann Surg 224:756-764, 1996 See "Note" following "References."; discussion 224:764-765, 1996
10. Ruegg C, Yilmaz A, Bieler G, et al: Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4:408-414, 1998
11. van Horssen R, ten Hagen TLM, Eggermont AMM: TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist 11:397-408, 2006